Registration Dossier

Administrative data

Description of key information

For the oral route, 4 acute toxicity studies in rats were identified, all indicating low acute oral toxicity for 1,3-Dioxolane, with a LD50 exceeding 2000 mg/kg bw. For the inhalation route, 3 acute toxicity studies in rats were identified, all indicating low acute inhalatory toxicity for 1,3-Dioxolane, with a LC50 of 68.4 mg/L (0.0684 mg/m3). There are no data on acute dermal toxicity.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Dose descriptor:
LC50
Value:
68 400 mg/m³

Additional information

For 1,3-Dioxolane, the acute oral toxicty in rats was >2000 mg/kg bw and needs not to be classified for acute oral toxicity.

The acute inhalation toxicity for 1,3-Dioxolane in rats was 68.4 mg/L, and based on these results, 1,3-Dioxolane needs not to be classified for acute inhalation toxicity.

Based on the observed lack of acute toxicity by the oral and inhalatory route, no acute dermal toxicty is to be expected. Therefore, 1,3-Dioxolane needs not to be classified for acute dermal toxicity.

Justification for classification or non-classification

According to CLP, 1,3-Dioxolane needs no classification for acute oral, dermal and inhalation toxicity.